(19)
(11) EP 3 886 820 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.05.2023 Bulletin 2023/20

(45) Mention of the grant of the patent:
12.04.2023 Bulletin 2023/15

(21) Application number: 19889873.6

(22) Date of filing: 27.11.2019
(51) International Patent Classification (IPC): 
A61K 9/48(2006.01)
A61K 47/10(2017.01)
A61K 47/40(2006.01)
 A61K 31/451(2006.01)
A61K 47/14(2017.01)
A61K 47/44(2017.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/4858; A61K 9/4825; A61K 47/10; A61K 47/14; A61K 47/40; A61K 47/44; A61K 31/451
(86) International application number:
PCT/US2019/063547
(87) International publication number:
WO 2020/112961 (04.06.2020 Gazette 2020/23)

(54)

CAPSULE FORMULATIONS

KAPSELFORMULIERUNGEN

FORMULATIONS DE CAPSULES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 30.11.2018 US 201862773848 P

(43) Date of publication of application:
06.10.2021 Bulletin 2021/40

(60) Divisional application:
23160271.5

(73) Proprietor: ChemoCentryx, Inc.
Thousand Oaks, CA 91320 (US)

(72) Inventors:
  • LELETI, Manmohan Reddy
    Dublin, California 94568 (US)
  • POWERS, Jay P.
    Pacifica, California 94044 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)


(56) References cited: : 
US-A1- 2007 298 099
US-A1- 2017 246 186
US-A1- 2018 280 530
 US-A1- 2010 311 753
US-A1- 2018 179 160
   
  • BEKKER et al.: "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS One, vol. 11, no. 10, 21 October 2016 (2016-10-21), pages 1-19, XP055602780,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).